SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report
(Date of earliest event reported): April 9, 2002

ARIAD PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware	0-21696	22-3106987
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

26 LANDSDOWNE STREET
CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code:
(617) 494-0400

TABLE OF CONTENTS

Ex-99.1 PRESS RELEASE DATED APRIL 9, 2002

ITEM 7.    FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

(c)	Exhibits.
	99.1      The Registrant’s Press Release dated April 9, 2002.

ITEM 9.    REGULATION FD DISCLOSURE

     On April 9, 2002, the Registrant publicly disseminated a Press Release announcing that the Company is presenting today, April 9, 2002, at the American Association for Cancer Research scientific meeting, results of preclinical studies on its lead anti-cancer drug candidate.

     The information contained in the Press Release dated April 9, 2002 is incorporated herein by reference and attached as Exhibit 99.1 hereto. This information is furnished, and not filed, pursuant to Item 9.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ARIAD PHARMACEUTICALS, INC.
By:	/s/ Brian A. Lajoie Brian A. Lajoie Interim Chief Financial Officer

Date: April 9, 2002

2

EXHIBIT INDEX

Exhibit
Number	Description	Sequential Page Number
99.1	The Registrant’s Press Release dated April 9, 2002.		4

3